No Detail Found!

Effectiveness of Nicorandil in Heart Failure: A Meta-Analysis

Author(s)
Tongge Mu School of Medicine, Shandong University of Traditional Chinese Medicine,Jinan,China
Kaixuan Tang School of Medicine, Shandong University of Traditional Chinese Medicine,Jinan,China
Yan Sun School of Medicine, Shandong University of Traditional Chinese Medicine,Jinan,China
Abstract
This meta-analysis aims to evaluate the e ectiveness of nicorandil in treating heart failure by synthesising evidence from diverse studies. The study period spanned from 12/01/2023 to 28/02/2024. Observational and randomised controlled trials have been conducted to study the cardiovascular outcomes associated with nicorandil. The ndings consistently show that nicorandil, administered either intravenously or orally, signi cantly reduces major adverse cardiovascular events (MACEs), lowers NT-proBNP levels, and improves left ventricular ejection fraction, indicating enhanced cardiac function. Nicorandil emerges as a promising adjunctive therapy in heart failure management, potentially improving patient outcomes and decreasing the risk of MACEs. However, the exact role of this therapy in heart failure treatment requires further research.
Publication Details
Page(s) 755-760
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 06, Year: 2025

Request the full text from PASTIC

Keywords
Meta-analysis, Heart failure, Cardiac function, major adverse cardiovascular events (MACEs), Nicorandil
References
Ponikowski P,Voors AA,Anker SD,Bueno H,Cleland JGF,Coats AJS .2016 .ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J, 10(27) : 2129-200.
Mentz RJ,O'Connor CM .2015 .Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol, 134(1) : 28-35.
McMurray JJ,Adamopoulos S,Anker SD,Auricchio A,Bohm M,Dickstein K .2012 .ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J, 10(14) : 1787-847.
Xanthakis V,Enserro DM,Larson MG,Wollert KC,Januzzi JL,Levy D .2016 .Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community. JACC Heart Fail, 05(10) : 808-15.
Bjork JB,Alton KK,Georgiopoulou VV,Butler J,Kalogeropoulos AP .2016 .De ning advanced heart failure: A systematic review of criteria used in clinical trials. J Card Fail, 03(7) : 569-77.
Frampton J,Buckley MM,Fitton A.,Nicorandil A. .1992 .A review of its pharmacology and therapeutic e cacy in angina pectoris. Drugs, 10(4) : 244040-00008.
Gvishiani M,Gabunia L,Makharadze T,Gongadze N. .2018 .Nicorandil e cacy in the treatment of ischemic heart disease (review). Georgian Med News, (28-1) : 152-5.
Ozcan C,Bienengraeber M,Dzeja PP .2001 .Terzic A. Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress at reoxygenation. Am J Physiol Heart Circ Physiol, 10(2) : H531-9.
Ahmed LA .2019 .Nicorandil: A drug with ongoing bene ts and di erent mechanisms in various diseased conditions. Indian J Pharmacol, 298(5) : 19-301.
Horinaka S. .2011 .Use of nicorandil in cardiovascular disease and its optimization. Drugs, 10(9) : 11592300-19.
Singh A,Laribi S,Teerlink JR,Mebazaa A .2017 .Agents with vasodilator properties in acute heart failure. Eur Heart J, 10(5) : 317-25.
Moher D,Liberati A,Tetzla J,Altman DG .2009 .6(7):e1000097. PLoS Med, 1000097 : .
Higgins JP,Thompson SG,Deeks JJ,Altman DG .2003 .Measuring inconsistency in meta-analyses. BMJ, 10 : 57-560.
Yoshihisa A,Sato Y,Watanabe S,Yokokawa T,Sato T,Suzuki S .2017 .Decreased cardiac mortality with nicorandil in patients with ischemic heart failure. BMC Cardiovasc Disord, 10(1) : 141.
Zhang Y,Cai Z,Ke X,Qiu W,Ke S,Wu Y. .2021 .E ectiveness and safety of intravenous nicorandil application in patients with acute heart failure with low baseline blood pressure. Heart Lung Circ, 06(1) : 95-100.
Yokota M,Horisawa T,Iwase M,Miyahara T,Yoshida J,Kamihara S .1987 .of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction. J Cardiovasc Pharmacol, 10(Suppl 8) : S116-22.
Kasama S,Toyama T,Funada R,Takama N,Koitabashi N,Ichikawa S . .E ects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients with acute decompensated heart failure. Eur J Nucl Med Mol Imaging2015, 10(5) : 761-70.
Ishihara S,Koga T,Kaseda S,Nyuta E,Haga Y,Fujishima S .2012 .of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome. Circ J, 11(5) : 1169-76.
Kasama S,Toyama T,Iwasaki T,Sumino H,Kumakura H,Minami K .2014 .E ects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: Subanalysis of our previous report using propensity score matching. Eur J Nucl Med Mol Imaging, 10(1) : 144-54.
Shirakabe A,Hata N,Yokoyama S,Shinada T,Kobayashi N,Asai K .2010 .and safety of nicorandil therapy in patients with acute heart failure. J Cardiol, 07(3) : 339-47.
Shigekiyo M .2012 .Harada K. Impact of nicorandil on renal function in patients with acute heart failure and pre-existing renal dysfunction. Eur Heart J, 33 : 7-8.
Harada K,Yamamoto T,Okumura T,Shigekiyo M,Terada N,Okada A .2017 .Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes: A randomised, controlled trial. Eur Heart J Acute Cardiovasc Care, 10(4) : 329-38.
Shigekiyo M,Harada K,Okada A,Terada N,Yoshikawa H,Hirono A .2011 .Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure: A randomised, controlled trial. Eur Heart J, 32 : 963.
Yamada T,Okuyama Y,Morita T,Furukawa Y,Tanaka K,Iwasaki Y .2009 .Long-term nicorandil therapy reverses left ventricular remodeling in patients with chronic heart failure: A randomized placebo-controlled study. Circulation, 120 : S887.
Galie N,Varani E,Maiello L,Boriani G,Boschi S,Binetti G .1990 .Usefulness of nicorandil in congestive heart failure. Am J Cardiol, 10(90) : 90299-g.
Krumenacker M,Roland E. .1992 .Clinical pro le of nicorandil: An overview of its hemodynamic properties and therapeutic e cacy. J Cardiovasc Pharmacol, 20(Suppl 3) : S93-102.
Yoneyama F,Satoh K,Taira N. .1990 .Nicorandil increases coronary blood ow predominantly by K-channel opening mechanism. Cardiovasc Drugs Ther, 10(4) : 1119-26.
Lopez JR,Jahangir R,Jahangir A,Shen WK,Terzic A .1996 .Potassium channel openers prevent potassium-induced calcium loading of cardiac cells: Possible implications in cardioplegia. J Thorac Cardiovasc Surg, 5223(96) : 70070-3.
Mizumura T,Nithipatikom K,Gross GJ K .1995 .E ects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil in ltration in the dog. Cardiovasc Res, 29(4) : 482-9.
Izawa H,Iwase M,Takeichi Y,Somura F,Nagata K,Nishizawa T .2003 .of nicorandil on left ventricular end-diastolic pressure during exercise in patients with hypertrophic cardiomyopathy. Eur Heart J, 10(03) : 00236-7.
Zhao F,Chaugai S,Chen P,Wang Y,Wang DW Y .2014 .E ect of nicorandil in patients with heart failure: A systematic review and meta-analysis. Cardiovasc Ther, 10(6) : 12097-5922.
Zhu Y,Xie S Y .2023 .Intravenous nicorandil for patients with acute decompensated heart failure: A meta-analysis of randomised controlled trials. Scand Cardiovasc J, 2220556(1) : 2220556.
0

Citations

0

Downloads

80

Views